Hollow fiber liquid phase microextraction with in situ derivatization for the determination of trace amounts of metformin hydrochloride (anti-diabetic drug) in biological fluids

Hollow fiber based liquid phase microextraction with high performance liquid chromatography for the determination of trace carvedilol (β-blocker) in biological fluids

A hollow-fiber liquid-phase microextraction (HF-LPME), followed by high-performance liquid chromatography–ultraviolet (HPLC–UV) method for the trace determination of carvedilol (β-blocker) in biological fluids, has been described. The separation was achieved using Inertsil ODS-3 C18 (250 mm × 4.6 mm, 3 μm) column with a mobile phase composition of 10 mM phosphate buffer (pH 4.0)–acetonitrile (50:50, v/v) at a flow rate of 1.0 mL/min, under isocratic elution. Several parameters (i.e., type of organic solvent, donor phase pH, concentration of acceptor phase (AP), stirring rate, extraction time, and salt addition) that affect the extraction efficiency were investigated. The optimum HF-LPME conditions were as follows: dihexyl ether as an organic solvent; donor phase pH, 10.7; 0.1 M HCl (AP); 1100-rpm stirring rate; 60-min extraction time; and no salt addition. These parameters have been confirmed using design of experiments. Under these conditions, an enrichment factor of 273-fold was achieved. Good linearity and correlation coefficient were obtained over the range 5–1000 ng/mL (r2 = 0.9994). Limits of detection and quantitation were 1.2 and 3.7 ng/mL, respectively. The relative standard deviation at 3 different concentration levels (5, 500, and 1000 ng/mL) were less than 13.2%. Recoveries for spiked urine and plasma were in the range 80.7–114%. The proposed method is simple, sensitive, and suitable for the determination of carvedilol in biological fluids.

A Facile Colorimetric and Spectrophotometric Method for Sensitive Determination of Metformin in Human Serum Based on Citrate-Capped Gold Nanoparticles: Central Composite Design Optimization

For the determination of Metformin in human serum, a facile colorimetric and spectrophotometric sensor was designed based on citrate-capped gold nanoparticles (citrate-GNPs). In this probe, the addition of Metformin to GNP solution generates a naked-eye color change resulting from the aggregation of GNPs. Study of this color conversion and quantity analysis of analyte is operated by spectrophotometric instruments. The three factors pH, time, and GNP ratio were selected to examine their effects on sensing results and their values optimization. The optimization of parameters was done by means of central composite design and one-at-a-time methods. The sensing results proved the highly selective and sensitive performance of the sensor for Metformin in a linear range of 6.25-133.3 ppm with a detection limit of 1.79 ppm. The relative standard deviation (RSD) of the reported method is 2.53%.

Electrochemically Modulated Liquid-Liquid Extraction for Sample Enrichment

A new sample preparation method is proposed for the extraction of pharmaceutical compounds (Metformin, Phenyl biguanide, and Phenformin) of varied hydrophilicity, dissolved in an aqueous sample. When in contact with an organic phase, an interfacial potential is imposed by the presence of an ion, tetramethylammonium (TMA⁺), common to each phase. The interfacial potential difference drives the transfer of ionic analytes across the interface and allows it to reach up to nearly 100% extraction efficiency and a 60-fold enrichment factor in optimized extraction conditions as determined by HPLC analysis.

Hydrophilic Interaction Liquid Chromatography-Electrospray Ionization Mass Spectrometry for Therapeutic Drug Monitoring of Metformin and Rosuvastatin in Human Plasma

In this work a hydrophilic interaction liquid chromatography/positive ion electrospray mass spectrometric assay (HILIC/ESI-MS) has been developed and fully validated for the quantitation of metformin and rosuvastatin in human plasma. Sample preparation involved the use of 100 μL of human plasma, following protein precipitation and filtration. Metformin, rosuvastatin and 4-[2-(propylamino) ethyl] indoline 2 one hydrochloride (internal standard) were separated by using an X-Bridge-HILIC BEH analytical column (150.0 × 2.1 mm i.d., particle size 3.5 μm) with isocratic elution. A mobile phase consisting of 12% (v/v) 15 mM ammonium formate water solution in acetonitrile was used for the separation and pumped at a flow rate of 0.25 mL min⁻¹. The linear range of the assay was 100 to 5000 ng mL⁻¹ and 2 to 100 ng mL⁻¹ for metformin and rosuvastatin, respectively. The current HILIC-ESI/MS method allows for the accurate and precise quantitation of metformin and rosuvastatin in human plasma with a simple sample preparation and a short a chromatographic run time (less than 15 min). Plasma samples from eight patients were further analysed proving the capability of the proposed method to support a wide range of clinical studies.

LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects

A specific and rapid liquid chromatography-tandem mass spectrometry method is proposed for the simultaneous determination of metformin (MET), saxagliptin (SAXA) and its active metabolite, 5-hydroxy saxagliptin (5-OH SAXA) in human plasma. Sample preparation was accomplished from 50 μL plasma sample by solid-phase extraction using sodium dodecyl sulfate as an ion-pair reagent. Reversed-phase chromatographic resolution of analytes was possible within 3.5 min on ACE 5CN (150 × 4.6 mm, 5 μm) column using acetonitrile and10.0 mm ammonium formate buffer, pH 5.0 (80:20, v/v) as the mobile phase. Triple quadrupole mass spectrometric detection was performed using electrospray ionization in the positive ionization mode. The calibration curves showed good linearity (r²  ≥ 0.9992) over the established concentration range with limit of quantification of 1.50, 0.10 and 0.20 ng/mL for MET, SAXA and 5-OH SAXA respectively. The extraction recoveries obtained from spiked plasma samples were highly consistent for MET (75.12-77.84%), SAXA (85.90-87.84%) and 5-OH SAXA (80.32-82.69%) across quality controls. The validated method was successfully applied to a bioequivalence study with a fixed-dose formulation consisting of 5 mg SAXA and 500 mg MET in 18 healthy subjects. The reproducibility of the assay was demonstrated by reanalysis of 87 incurred samples.

Determination of α-ketoglutaric and pyruvic acids in urine as potential biomarkers for diabetic II and liver cancer

Background: A simple and sensitive hollow fiber-liquid phase microextraction with in situ derivatization method was developed for the determination of α-ketoglutaric (α-KG) and pyruvic acids (PA) in small-volume urine samples. 2,4,6-trichloro phenyl hydrazine was used as derivatization agent. Results: Under the optimum extraction conditions, enrichment factors of 742 and 400 for α-KG and PA, respectively, were achieved. Calibration curves were linear over the range 1 to 1000 ng/ml (r2 ≥ 0.998). Detection and quantitation limits were 0.03 and 0.02, and 0.10 and 0.05 ng/ml for α-KG and PA, respectively. Conclusion: The concentrations in diabetic II and liver cancer samples were significantly lower than those from healthy people, showing their potential as biomarkers for these diseases.